According to MedPage Today (9/12, DePeau-Wilson), psychiatric care professionals “most often ranked the side effect profile of long-acting injectables (LAIs) for schizophrenia as the top consideration when prescribing the antipsychotics to patients,” researchers concluded in the findings of a 380-respondent, “survey-based study” presented in a poster at Psych Congress 2023. Among those respondents, “33% cited the safety/tolerability profile as key when selecting an LAI, with 16% to 21% of the respondents citing patient preference, the particular molecule in the LAI, access, or product attributes like dosing intervals or injection site as most important.”
Related Links:
— MedPage Today (requires login and subscription)